World Allergy Organization Journal最新文献

筛选
英文 中文
Allergic rhinitis as a potentially modifiable contributor to small airway dysfunction and incomplete clinical remission in severe asthma 变应性鼻炎是严重哮喘患者小气道功能障碍和不完全临床缓解的潜在可改变因素
IF 4 2区 医学
World Allergy Organization Journal Pub Date : 2026-11-01 Epub Date: 2026-10-28 DOI: 10.1016/j.waojou.2026.101484
Huan Wu, Qin Ouyang MD, PhD
{"title":"Allergic rhinitis as a potentially modifiable contributor to small airway dysfunction and incomplete clinical remission in severe asthma","authors":"Huan Wu, Qin Ouyang MD, PhD","doi":"10.1016/j.waojou.2026.101484","DOIUrl":"10.1016/j.waojou.2026.101484","url":null,"abstract":"","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"19 11","pages":"Article 101484"},"PeriodicalIF":4.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149353764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biologic therapies for atopic diseases during pregnancy: A World Allergy Organization survey 妊娠期特应性疾病的生物治疗:世界过敏组织调查
IF 4 2区 医学
World Allergy Organization Journal Pub Date : 2026-11-01 Epub Date: 2026-11-03 DOI: 10.1016/j.waojou.2026.101485
Sergio E. Chiarella MD, Isabella Novoa-Caicedo MD, Sarah M. Jenkins MS, Divya Shah MD, Ishitha Jagadish MD, Leah Ishmael DO, Fnu Shakuntulla MD, Andrea Sitek MD, Barbara Kong-Cardoso MD, Isabel Fernandez de Alba MD, Duy Le Pham MD, PhD, Agnes Sze-yin Leung MBChB, Daria Levina MD, MSc, Shun Chi Ryan Lo MD, Matthew Norris MD, Nida Öztop MD, Thulja Trikamjee MD, Rosalaura Villarreal-Gonzalez MD, PhD, Yichao Wang MD, PhD, Lyda Cuervo-Pardo MD, Luciana Kase Tanno MD, PhD
{"title":"Biologic therapies for atopic diseases during pregnancy: A World Allergy Organization survey","authors":"Sergio E. Chiarella MD,&nbsp;Isabella Novoa-Caicedo MD,&nbsp;Sarah M. Jenkins MS,&nbsp;Divya Shah MD,&nbsp;Ishitha Jagadish MD,&nbsp;Leah Ishmael DO,&nbsp;Fnu Shakuntulla MD,&nbsp;Andrea Sitek MD,&nbsp;Barbara Kong-Cardoso MD,&nbsp;Isabel Fernandez de Alba MD,&nbsp;Duy Le Pham MD, PhD,&nbsp;Agnes Sze-yin Leung MBChB,&nbsp;Daria Levina MD, MSc,&nbsp;Shun Chi Ryan Lo MD,&nbsp;Matthew Norris MD,&nbsp;Nida Öztop MD,&nbsp;Thulja Trikamjee MD,&nbsp;Rosalaura Villarreal-Gonzalez MD, PhD,&nbsp;Yichao Wang MD, PhD,&nbsp;Lyda Cuervo-Pardo MD,&nbsp;Luciana Kase Tanno MD, PhD","doi":"10.1016/j.waojou.2026.101485","DOIUrl":"10.1016/j.waojou.2026.101485","url":null,"abstract":"<div><h3>Rationale</h3><div>Biologic therapies are an increasingly important treatment option for atopic diseases, which commonly affect women of reproductive age. However, global barriers to prescribing biologic therapies to pregnant patients remain poorly understood.</div></div><div><h3>Methods</h3><div>The World Allergy Organization (WAO) Junior Members Steering Group conducted a global, web-based survey of healthcare professionals to evaluate prescribing patterns and barriers to the use of biologic therapies for atopic diseases during pregnancy.</div></div><div><h3>Results</h3><div>From 322 total participants representing 71 countries, 77 of 314 (24.5%) reported prescribing biologic therapies for atopic diseases during pregnancy. The most frequently prescribed biologic therapies during pregnancy were omalizumab (79.2%) and dupilumab (32.5%), followed by benralizumab (7.8%), mepolizumab (7.8%), tralokinumab (3.9%), tezepelumab (2.6%), and reslizumab (1.3%). Twenty-three respondents encountered barriers to prescribing biologic therapies to pregnant patients, including patients’ concerns about the impact on pregnancy (82.6%), adverse reactions (47.8%), difficulty securing insurance coverage (13.0%), and high patient costs (8.7%). Reported biologic therapies discontinued due to pregnancy included dupilumab (39.1%), mepolizumab (26.1%), omalizumab (26.1%), and benralizumab (13.0%). Twelve of the 23 healthcare professionals who discontinued biologic therapies reported that their pregnant patients experienced worsening symptoms after stopping. Seven respondents (9.9%) reported adverse maternal or fetal outcomes in pregnant patients receiving biologic treatment for atopic diseases, including allergic/immune disorders (3), congenital defects (2), miscarriage (1), and preeclampsia (1). Only 42.3% of respondents who prescribed biologics to pregnant patients reported enrolling these patients in a pregnancy registry.</div></div><div><h3>Conclusions</h3><div>Significant barriers limit the prescriptions of biologic therapies for atopic diseases during pregnancy. Multidisciplinary collaboration among clinicians, researchers, and the pharmaceutical industry is essential for developing strategies to overcome these barriers and improve access to biologic therapy for pregnant patients.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"19 11","pages":"Article 101485"},"PeriodicalIF":4.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149353766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical utility of Oriton IgE CHEMIPHAR™ for predicting skin prick test positivity in patients with allergic airway diseases Oriton IgE CHEMIPHAR™用于预测过敏性气道疾病患者皮肤点刺试验阳性的临床应用
IF 4 2区 医学
World Allergy Organization Journal Pub Date : 2026-11-01 Epub Date: 2026-11-02 DOI: 10.1016/j.waojou.2026.101479
Erika Naito MD, Tomoyuki Soma MD, PhD, Kazuyuki Nakagome MD, PhD, Ryu Sekiya MD, Yoshitaka Uchida MD, PhD, Takehito Kobayashi MD, PhD, Makoto Nagata MD, PhD
{"title":"Clinical utility of Oriton IgE CHEMIPHAR™ for predicting skin prick test positivity in patients with allergic airway diseases","authors":"Erika Naito MD,&nbsp;Tomoyuki Soma MD, PhD,&nbsp;Kazuyuki Nakagome MD, PhD,&nbsp;Ryu Sekiya MD,&nbsp;Yoshitaka Uchida MD, PhD,&nbsp;Takehito Kobayashi MD, PhD,&nbsp;Makoto Nagata MD, PhD","doi":"10.1016/j.waojou.2026.101479","DOIUrl":"10.1016/j.waojou.2026.101479","url":null,"abstract":"<div><h3>Introduction</h3><div>Skin prick testing (SPT) and the measurement of serum allergen-specific IgE antibodies are common diagnostic tools for allergic diseases. Oriton IgE CHEMIPHAR™ (CHEMIPHAR) is a simple and convenient serological assay for assessing allergen-specific IgE antibody levels that enables rapid clinical decision-making. However, its clinical application remains limited. The current study evaluated the analytical performance and clinical relevance of CHEMIPHAR in identifying SPT positivity.</div></div><div><h3>Methods</h3><div>Patients with allergic airway diseases were assessed for SPT positivity and serum allergen-specific IgE antibody levels against 10 common aeroallergens in Japan. Serum-specific IgE antibodies were measured using CHEMIPHAR and ImmunoCAP. The concordance between CHEMIPHAR and SPT was evaluated and compared with that between ImmunoCAP and SPT.</div></div><div><h3>Results</h3><div>In 168 eligible patients, 168 CHEMIPHAR assays, 139 SPTs, and 108 ImmunoCAP assays were performed. The positivity rate for Japanese cedar pollen (JCP) was the highest across all methods, followed by <em>Dermatophagoides farinae</em> (<em>Df</em>). Meanwhile, the positivity rate for <em>Aspergillus</em> and <em>Alternaria</em> was low. The positivity rates for allergens with moderate prevalence varied among the methods. Overall, the concordance with SPT was high for both assay systems for most allergens, except for cat dander. The sensitivity for SPT positivity varied by allergen, with high sensitivity observed for JCP, <em>Df</em>, and orchard grass, and lower sensitivity for pet dander in both systems, and for fungal allergens with CHEMIPHAR compared with ImmunoCAP. The specificity for JCP was higher with CHEMIPHAR than with ImmunoCAP. Meanwhile, the specificity for the remaining allergens was similarly high with both systems. CHEMIPHAR showed significant AUC values for a greater number of inhalant allergens than ImmunoCAP. The Kappa coefficients confirmed the agreement with SPT, ranging from substantial agreement for JCP and <em>Df</em> with CHEMIPHAR and for <em>Df</em> with ImmunoCAP, to fair agreement for three fungal allergens and cat dander with CHEMIPHAR and for <em>Candida</em> with ImmunoCAP.</div></div><div><h3>Conclusion</h3><div>CHEMIPHAR had a clinically relevant performance in identifying allergen sensitization, and it showed concordance with SPT comparable with that of ImmunoCAP. Based on these findings, CHEMIPHAR can be a practical alternative assay for diagnosing allergen sensitization.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"19 11","pages":"Article 101479"},"PeriodicalIF":4.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149353768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Executive Summary of the 2025 World Allergy Organization Guidelines for Hereditary Angioedema 2025年世界过敏组织遗传性血管性水肿指南执行摘要。
IF 4 2区 医学
World Allergy Organization Journal Pub Date : 2026-11-01 Epub Date: 2026-10-27 DOI: 10.1016/j.waojou.2026.101481
Pedro Giavina-Bianchi MD, PhD, Daniel O. Vazquez MD, Dario Josviack MD, Allen P. Kaplan MD, Pablo A.S. Martinez BSc, Claudio A. Fantini MD, Jonathan A. Bernstein MD, Bryan L. Martin DO, Ignacio J. Ansotegui MD, PhD, Timothy J. Craig DO, Mário Morais-Almeida MD
{"title":"Executive Summary of the 2025 World Allergy Organization Guidelines for Hereditary Angioedema","authors":"Pedro Giavina-Bianchi MD, PhD,&nbsp;Daniel O. Vazquez MD,&nbsp;Dario Josviack MD,&nbsp;Allen P. Kaplan MD,&nbsp;Pablo A.S. Martinez BSc,&nbsp;Claudio A. Fantini MD,&nbsp;Jonathan A. Bernstein MD,&nbsp;Bryan L. Martin DO,&nbsp;Ignacio J. Ansotegui MD, PhD,&nbsp;Timothy J. Craig DO,&nbsp;Mário Morais-Almeida MD","doi":"10.1016/j.waojou.2026.101481","DOIUrl":"10.1016/j.waojou.2026.101481","url":null,"abstract":"","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"19 11","pages":"Article 101481"},"PeriodicalIF":4.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13735166/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149344674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Landscape of hereditary angioedema in China: A multicenter cross-sectional questionnaire survey 中国遗传性血管性水肿景观:一项多中心横断面问卷调查
IF 4 2区 医学
World Allergy Organization Journal Pub Date : 2026-11-01 Epub Date: 2026-11-04 DOI: 10.1016/j.waojou.2026.101483
Yingyang Xu MD, Wei Chen MD, Timothy Craig MD, PhD, Shan Deng MD, Yinshi Guo MD, Henry H. Li MD, PhD, Philip H. Li MD, Yingnan Li MD, Ruiling Liu MD, Han Ma MD, Yan Ma MD, Chunrui Shi MD, Huichun Su MD, Yuemei Sun MD, Siqing Wang MD, Yan Wang MD, PhD, Qingyu Wei MD, Lingying Wu MD, Yongmei Yu MD, Dan Zeng MD, Yuxiang Zhi MD
{"title":"Landscape of hereditary angioedema in China: A multicenter cross-sectional questionnaire survey","authors":"Yingyang Xu MD,&nbsp;Wei Chen MD,&nbsp;Timothy Craig MD, PhD,&nbsp;Shan Deng MD,&nbsp;Yinshi Guo MD,&nbsp;Henry H. Li MD, PhD,&nbsp;Philip H. Li MD,&nbsp;Yingnan Li MD,&nbsp;Ruiling Liu MD,&nbsp;Han Ma MD,&nbsp;Yan Ma MD,&nbsp;Chunrui Shi MD,&nbsp;Huichun Su MD,&nbsp;Yuemei Sun MD,&nbsp;Siqing Wang MD,&nbsp;Yan Wang MD, PhD,&nbsp;Qingyu Wei MD,&nbsp;Lingying Wu MD,&nbsp;Yongmei Yu MD,&nbsp;Dan Zeng MD,&nbsp;Yuxiang Zhi MD","doi":"10.1016/j.waojou.2026.101483","DOIUrl":"10.1016/j.waojou.2026.101483","url":null,"abstract":"<div><h3>Background</h3><div>Significant progress has been made in the clinical awareness and management of Hereditary angioedema (HAE) in China in recent years. This study aims to comprehensively evaluate the current status of HAE in China through a multicenter cross-sectional questionnaire survey.</div></div><div><h3>Methods</h3><div>This study employed an online questionnaire survey targeting major public hospitals in China that manage confirmed HAE cases. The questionnaire covered 3 dimensions: number of cases, analysis of diagnostic pathways, and therapy accessibility.</div></div><div><h3>Results</h3><div>Twenty valid questionnaires were collected across 18 regions in China, including the mainland and the Hong Kong Special Administrative Region (SAR). The study aggregated 1097 confirmed HAE cases, with HAE with C1 inhibitor (C1–INH) dysfunction (HAE-C1-INH) Type 1, HAE-C1-INH- Type 2HAE-C1-INH-1HAE-C1-INH-2, and HAE with normal C1-INHaccounting for 94.8%, 4.2%, and 1.0% of cases, respectively. The number of confirmed cases was significantly lower than estimates based on international prevalence rates, indicating substantial underdiagnosis in China. Among the participating hospitals, only 5 could perform clinical C1–INH antigen level testing. C1–INH functional testing is not approved for clinical use in mainland China and is only routinely available in Hong Kong SAR. In the participating hospitals, 75% have icatibant, and 80% have lanadelumab, which are covered by the National Reimbursement. Additionally, several clinical trials are undergoing, including C1–INH replacement, BW-20805, PHVS416/PHVS719, garadacimab, STAR-0215, and ADX-324.</div></div><div><h3>Conclusions</h3><div>The number of confirmed HAE patients in China remains markedly lower than estimates derived from international prevalence rates, suggesting substantial underdiagnosis. Standardized C1–INH antigen level and functional assays are not widely available nationwide. Although accessibility of first-line therapies has improved and multiple clinical trials are ongoing, the repertoire of marketed therapeutic agents in China remains limited.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"19 11","pages":"Article 101483"},"PeriodicalIF":4.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149353765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Olive allergens under the microscope: Ole e 7 and Ole e 9 sensitization does not increase symptom severity or adverse reactions to subcutaneous allergen immunotherapy 显微镜下的橄榄过敏原:Ole e7和Ole e9致敏不会增加皮下过敏原免疫治疗的症状严重程度或不良反应
IF 4 2区 医学
World Allergy Organization Journal Pub Date : 2026-11-01 Epub Date: 2026-11-04 DOI: 10.1016/j.waojou.2026.101482
Manuel Alcántara Villar PhD, MD, Alicia López Guerrero MD, Miriam Bermúdez Bejarano MD, Cristina Ruiz González MD, Patricia de Manueles Tabliega MD, Guillermo Salamanca Fernández PhD
{"title":"Olive allergens under the microscope: Ole e 7 and Ole e 9 sensitization does not increase symptom severity or adverse reactions to subcutaneous allergen immunotherapy","authors":"Manuel Alcántara Villar PhD, MD,&nbsp;Alicia López Guerrero MD,&nbsp;Miriam Bermúdez Bejarano MD,&nbsp;Cristina Ruiz González MD,&nbsp;Patricia de Manueles Tabliega MD,&nbsp;Guillermo Salamanca Fernández PhD","doi":"10.1016/j.waojou.2026.101482","DOIUrl":"10.1016/j.waojou.2026.101482","url":null,"abstract":"<div><h3>Background</h3><div>In regions with prolonged and intense exposure to olive pollen, sensitization to minor allergens such as Ole e 7 and Ole e 9 and their specific IgE levels tend to increase. This has raised concerns regarding a potentially higher risk of adverse reactions during allergen immunotherapy.</div></div><div><h3>Objective</h3><div>To assess subcutaneous immunotherapy (SCIT) safety and the clinical outcomes observed after 1 year of treatment in routine clinical practice in patients with olive pollen–induced allergic respiratory disease, according to their molecular sensitization profiles.</div></div><div><h3>Methods</h3><div>This retrospective observational study included patients with rhinitis and/or asthma caused by olive pollen sensitization who received SCIT with a depigmented, polymerized olive pollen extract. Olive allergen sensitization profiles were determined using component-resolved diagnosis, and their association with disease severity, treatment tolerance, and clinical response was assessed.</div></div><div><h3>Results</h3><div>A total of 196 patients were included in the analysis. Rhinitis was present in 97% of patients and asthma in 94%, predominantly of moderate persistent severity. Sensitization to Ole e 1 was observed in 96% of patients, whereas 73% and 68% were sensitized to Ole e 7 and Ole e 9, respectively; 58% were sensitized to all 3 components. Six late local reactions and 1 grade 3 systemic reaction (EAACI classification) were reported. Clinical improvement according to the predefined clinical response criteria was observed in 76% of patients, along with a reduction in rescue medication use and a decrease in the number of patients requiring emergency department visits, from 60 at baseline to none after 1 year of follow-up. No association was observed between molecular sensitization profiles and SCIT tolerability or clinical response.</div></div><div><h3>Conclusion</h3><div>SCIT with a depigmented polymerized olive pollen extract was well tolerated and was associated with favorable one-year clinical outcomes in a population with high environmental exposure to olive pollen, irrespective of sensitization to minor olive allergens.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"19 11","pages":"Article 101482"},"PeriodicalIF":4.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149353767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting the CD74-MHC II axis with allergen-specific immunotherapy ameliorates pollen-induced allergic asthma 用过敏原特异性免疫疗法靶向CD74-MHC II轴可改善花粉诱导的过敏性哮喘
IF 4 2区 医学
World Allergy Organization Journal Pub Date : 2026-11-01 Epub Date: 2026-10-28 DOI: 10.1016/j.waojou.2026.101478
Wenhua Ming, Yang Zhou, Tingting Liu, Hongtian Wang, Xueyan Wang, Tingting Ma
{"title":"Targeting the CD74-MHC II axis with allergen-specific immunotherapy ameliorates pollen-induced allergic asthma","authors":"Wenhua Ming,&nbsp;Yang Zhou,&nbsp;Tingting Liu,&nbsp;Hongtian Wang,&nbsp;Xueyan Wang,&nbsp;Tingting Ma","doi":"10.1016/j.waojou.2026.101478","DOIUrl":"10.1016/j.waojou.2026.101478","url":null,"abstract":"<div><h3>Background</h3><div>The incidence and prevalence of allergic asthma are increasing year by year, making it one of the major public health concerns affecting human health. <em>Artemisia annua</em> (<em>A. annua</em>) pollen is a key allergen responsible for allergic asthma in northern China. Allergen-specific immunotherapy (AIT), including subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT), is an important strategy for the treatment of allergic diseases. The aim of this study was to investigate the effect of <em>A. annua</em> allergen-specific immunotherapy (AIT) on allergic asthma and its potential mechanism.</div></div><div><h3>Methods</h3><div>An <em>Artemisia annua</em>-induced allergic asthma mouse model was established by subcutaneous sensitization plus aerosol challenge. Methacholine challenge, Wright–Giemsa, H&amp;E and AB–PAS staining were used to validate the model and assess specific immunotherapy efficacy. Inflammatory factors in bronchoalveolar lavage fluid (BALF) and lung tissues were detected via ELISA and high-throughput Luminex assay. Proteomic analysis explored the potential mechanism of SCIT, with results verified by Western blot and immunofluorescence. Our preclinical data identified CD74-enriched immune cell subsets in human peripheral blood mononuclear cells (PBMCs) by using Flow cytometry.</div></div><div><h3>Results</h3><div>Compared with the control group, asthmatic mice exhibited significantly increased airway hyperresponsiveness, serum IgE, IgG1 and IgG2a levels, BALF inflammatory cell counts, IL-1β and TNF-α secretion, as well as severe peribronchial inflammatory infiltration. Lung tissue expression of IL-5, IL-3, CCL2 and TNF-α was also markedly elevated. Notably, SCIT treatment significantly ameliorated these abnormalities except for serum total IgE, IgG1 and IgG2a. Moreover, SCIT inhibited the asthma-induced upregulation of CD74, MHC-II, CD11c and GATA3, and significantly increased FOXP3 expression.</div><div>Consistently, flow cytometric analysis of human peripheral blood mononuclear cells (PBMCs) revealed elevated CD74-MHC-II axis expression on plasmacytoid dendritic cells (pDCs) in asthmatic participants, with a prominent downward tendency observed following SLIT treatment.</div></div><div><h3>Conclusions</h3><div>In conclusion, <em>Artemisia annua</em> pollen-specific immunotherapy alleviates airway inflammation and hyperresponsiveness in allergic asthma and attenuated GATA3-related type 2 inflammation, possibly in association with inhibition of CD74-MHC-II axis activation within plasmacytoid dendritic cells.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"19 11","pages":"Article 101478"},"PeriodicalIF":4.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149353170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
World Allergy Organization Sublingual Immunotherapy Position Paper: 2026 update 世界过敏组织舌下免疫治疗立场文件:2026年更新:关于疗效、安全性、疾病改变和实施的全球专家共识。
IF 4 2区 医学
World Allergy Organization Journal Pub Date : 2026-10-01 Epub Date: 2026-09-26 DOI: 10.1016/j.waojou.2026.101442
Giorgio Walter Canonica MD, Mário Morais-Almeida MD, Danilo Di Bona MD, PhD, Ignacio J. Ansotegui MD, PhD, John J. Oppenheimer MD, Maryam Al-Nesf MD, ABHS, MSc, PhD, Jonathan A. Bernstein MD, Davide Caimmi MD, PhD, Yoon-Seok Chang MD, PhD, Carla M. Davis MD, Motohiro Ebisawa MD, PhD, Alessandro Fiocchi MD, R. Maximiliano Gómez MD, PhD, Sandra N. González-Díaz MD, PhD, Soon Jong Hong MD, PhD, Nikolaos G. Papadopoulos MD, PhD, Ruby Pawankar MD, PhD, Jonny G. Peter MB ChB, MMed, FCP(SA), PhD, María Isabel Rojo Gutiérrez MD, Pongsakorn Tantilipikorn MD, PhD, Bryan L. Martin DO, MMAS
{"title":"World Allergy Organization Sublingual Immunotherapy Position Paper: 2026 update","authors":"Giorgio Walter Canonica MD,&nbsp;Mário Morais-Almeida MD,&nbsp;Danilo Di Bona MD, PhD,&nbsp;Ignacio J. Ansotegui MD, PhD,&nbsp;John J. Oppenheimer MD,&nbsp;Maryam Al-Nesf MD, ABHS, MSc, PhD,&nbsp;Jonathan A. Bernstein MD,&nbsp;Davide Caimmi MD, PhD,&nbsp;Yoon-Seok Chang MD, PhD,&nbsp;Carla M. Davis MD,&nbsp;Motohiro Ebisawa MD, PhD,&nbsp;Alessandro Fiocchi MD,&nbsp;R. Maximiliano Gómez MD, PhD,&nbsp;Sandra N. González-Díaz MD, PhD,&nbsp;Soon Jong Hong MD, PhD,&nbsp;Nikolaos G. Papadopoulos MD, PhD,&nbsp;Ruby Pawankar MD, PhD,&nbsp;Jonny G. Peter MB ChB, MMed, FCP(SA), PhD,&nbsp;María Isabel Rojo Gutiérrez MD,&nbsp;Pongsakorn Tantilipikorn MD, PhD,&nbsp;Bryan L. Martin DO, MMAS","doi":"10.1016/j.waojou.2026.101442","DOIUrl":"10.1016/j.waojou.2026.101442","url":null,"abstract":"<div><h3>Background</h3><div>Sublingual immunotherapy (SLIT) is a well-established form of allergen immunotherapy with demonstrated efficacy and a favorable safety profile in IgE-mediated allergic diseases, particularly in allergic rhinitis and allergic asthma. Since the publication of previous World Allergy Organization (WAO) position papers, accumulating evidence and expanding global clinical experience has justified an updated, internationally harmonized framework to guide the appropriate use of SLIT across diverse healthcare settings.</div></div><div><h3>Methods</h3><div>An international panel of experts developed an updated Position Paper on SLIT using a structured Delphi consensus methodology. Statements were formulated based on a targeted review of the scientific literature and expert clinical experience, addressing indications, patient selection, safety, treatment duration, adherence, biomarkers, disease modification, and implementation domains. Two rounds of anonymous electronic voting were conducted. Consensus was predefined as ≥70% agreement (scores 4–5 on a 5-point Likert scale).</div></div><div><h3>Results</h3><div>Eighty-three experts representing all WAO regions were invited, and seventy-eight of them participated in the Delphi process. High levels of consensus were achieved for core principles, including SLIT effectiveness, safety, the importance of appropriate patient selection, a minimum treatment duration of 3 years, supervised administration of the first dose followed by home-based treatment, and the central role of adherence and regular follow-up. Consensus regarding disease-modifying effects was stronger for children and adolescents than for adults. Lower consensus was observed on topics related to regional allergens, likely influenced by differences in allergen exposure, product availability, clinical experience, and regulatory contexts; however, formal region-stratified analyses were not performed.</div></div><div><h3>Conclusions</h3><div>This WAO Position Paper establishes a globally applicable, evidence-informed consensus framework for the positioning and implementation of SLIT. By clearly delineating areas of strong agreement and domains of conditional or context-dependent evidence, it provides both a clinical reference and a strategic roadmap for equitable and sustainable SLIT integration worldwide.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"19 10","pages":"Article 101442"},"PeriodicalIF":4.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13636449/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149118588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adverse health outcomes and patient and physician perspectives of attenuated androgen use in hereditary angioedema 遗传性血管性水肿患者雄激素使用减少的不良健康结果及患者和医生的观点
IF 4 2区 医学
World Allergy Organization Journal Pub Date : 2026-10-01 Epub Date: 2026-09-22 DOI: 10.1016/j.waojou.2026.101471
Markus Magerl MD, Anete S. Grumach MD, PhD, Noemi Fluetsch Brennan MSc, MPH, Adam Gordois MSc, Maria Pedrosa MD, PhD, Nikolina Boskovic MPH, Lisa Bloudek PharmD, Sandra Nestler-Parr PhD, Patrick Gillard PharmD, Marcin Stobiecki MD, Sorena Kiani-Alikhan MD, PhD
{"title":"Adverse health outcomes and patient and physician perspectives of attenuated androgen use in hereditary angioedema","authors":"Markus Magerl MD,&nbsp;Anete S. Grumach MD, PhD,&nbsp;Noemi Fluetsch Brennan MSc, MPH,&nbsp;Adam Gordois MSc,&nbsp;Maria Pedrosa MD, PhD,&nbsp;Nikolina Boskovic MPH,&nbsp;Lisa Bloudek PharmD,&nbsp;Sandra Nestler-Parr PhD,&nbsp;Patrick Gillard PharmD,&nbsp;Marcin Stobiecki MD,&nbsp;Sorena Kiani-Alikhan MD, PhD","doi":"10.1016/j.waojou.2026.101471","DOIUrl":"10.1016/j.waojou.2026.101471","url":null,"abstract":"<div><div>Attenuated androgens (AAs) historically have been used as long-term prophylaxis (LTP) for hereditary angioedema (HAE), and they continue to be used, especially in regions where access to newer therapies remains restricted. This systematic literature review assessed the adverse health outcomes associated with AAs, including adverse events (AEs), comorbidities, cardiovascular (CV) risk, as well as patient and physician perspectives. In total, 99 unique studies were identified through MEDLINE and EMBASE (searches up to March 2025), of which the majority were conducted in Europe (n = 57) and the United States (n = 26). Commonly reported adverse outcomes included weight gain, menstrual irregularities, virilization, myalgia, acne, and liver damage. Long-term use (≥5 years) of AAs, even at low doses, was associated with coagulation activation, hypertension, hypercholesterolemia, and hepatocellular carcinoma, a rare but serious AE. Studies also noted unfavorable changes in lipid profiles and markers of inflammation and endothelial dysfunction. Patients and physicians highlighted concerns over tolerability, AEs, and poor adherence. Notably, based on 3 serial surveys, physician reluctance to prescribe AAs rose from 18% in 2010 to 60% in 2019, likely reflecting the availability of alternative options. These findings underscore the need for improved access to targeted therapies for HAE and more research into the long-term CV risks of AAs.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"19 10","pages":"Article 101471"},"PeriodicalIF":4.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149156278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral 5-HT3 receptor antagonist for at-home management of acute FPIES episodes in adults: A real-world observational study 口服5-HT3受体拮抗剂用于成人急性FPIES发作的家庭管理:一项现实世界的观察研究
IF 4 2区 医学
World Allergy Organization Journal Pub Date : 2026-10-01 Epub Date: 2026-09-22 DOI: 10.1016/j.waojou.2026.101473
Sho Watanabe MD, PhD, Ayako Sato MD, PhD, Hiroto Seki MD, Tsunehito Yauchi MD, Kiwako Yamamoto-Hanada MD, PhD, Tatsuki Fukuie MD, PhD, Yukihiro Ohya MD, PhD, Ichiro Nomura MD, PhD
{"title":"Oral 5-HT3 receptor antagonist for at-home management of acute FPIES episodes in adults: A real-world observational study","authors":"Sho Watanabe MD, PhD,&nbsp;Ayako Sato MD, PhD,&nbsp;Hiroto Seki MD,&nbsp;Tsunehito Yauchi MD,&nbsp;Kiwako Yamamoto-Hanada MD, PhD,&nbsp;Tatsuki Fukuie MD, PhD,&nbsp;Yukihiro Ohya MD, PhD,&nbsp;Ichiro Nomura MD, PhD","doi":"10.1016/j.waojou.2026.101473","DOIUrl":"10.1016/j.waojou.2026.101473","url":null,"abstract":"<div><h3>Background</h3><div>Food protein–induced enterocolitis syndrome (FPIES) is increasingly recognized in adults. Because adults encounter diverse food environments, ingestion of trigger foods may occur despite dietary avoidance. However, the real-world occurrence of post-diagnosis FPIES episodes and strategies for at-home management remain poorly described. We aimed to characterize post-diagnosis FPIES episodes in adults and evaluate the real-world use of orally administered granisetron as a patient-initiated rescue treatment.</div></div><div><h3>Methods</h3><div>We conducted a retrospective observational study of adults diagnosed with FPIES between April 2023 and March 2025. Post-diagnosis FPIES episodes were recorded using patient diaries and a secure web-based reporting system. Patients were instructed to take granisetron (1 mg) when gastrointestinal symptoms developed after ingestion of a known trigger food. The primary outcome was time from granisetron intake to patient-reported symptom resolution. Time-to-event analyses were performed using Kaplan–Meier methods.</div></div><div><h3>Results</h3><div>Thirty-three FPIES episodes in 12 adults were treated with granisetron. Abdominal distention (84.8%), abdominal pain (75.8%), nausea (63.6%), and diarrhea (39.4%) were the most common symptoms. The median interval from symptom onset to granisetron intake was 30 min, and the median time from intake to symptom resolution was 50 min. Kaplan–Meier analysis showed symptom resolution rates of 45.5% at 30 min, 81.8% at 60 min, and 87.9% at 90 min. No emergency transport or intravenous treatment was required, and only mild constipation occurred in 2 episodes.</div></div><div><h3>Conclusion</h3><div>Oral granisetron may be associated with rapid symptom improvement and represent a potential patient-initiated option for at-home management of acute FPIES episodes in adults.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"19 10","pages":"Article 101473"},"PeriodicalIF":4.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149156614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书